SAN DIEGO -- A novel therapy for polycythemia vera (PCV) maintained stable hematocrit levels for as long as 2.5 years and significantly reduced use of phlebotomy, a small randomized trial showed. The ...

Please provide your email address to receive an email when new articles are posted on . High hematocrit levels were observed among 8.4% of adults receiving gender-confirming testosterone therapy.

Credit: Thinkstock. The risk of hematocrit elevation may depend on testosterone therapy's route of administration, according to investigators. A rise in hematocrit levels occurs with 4 months of ...

Researchers explored the incidence of erythrocytosis in the first 20 months of testosterone therapy among people receiving gender-affirming hormone therapy (GAHT). Specifically, they conducted a ...

Every year, millions of newborns—especially those born premature, underweight or sick—are at risk of neonatal hypoglycemia, a dangerous drop in blood sugar that can lead to seizures, brain injury and ...

Every year, millions of newborns—especially those born premature, underweight or sick—are at risk of neonatal hypoglycemia, a dangerous drop in blood sugar that can lead to seizures, brain injury and ...

SGLT2 inhibitors significantly improve hemoglobin and hematocrit levels in CKD patients, enhancing anemia management. The KDIGO 2024 guideline endorses SGLT2 inhibitors for CKD patients, highlighting ...

Please provide your email address to receive an email when new articles are posted on . Induction therapy with twice-weekly rusfertide helped patients with polycythemia vera achieve target hematocrit ...

Rusfertide effectively maintained hematocrit control below 45% and reduced phlebotomy eligibility in PV patients through 52 weeks. Patients switching from placebo to rusfertide achieved rapid and ...

The use of testosterone as gender-affirming hormone therapy (GAHT) among transgender men is associated with a lower risk for erythrocytosis (abnormal blood cell elevation) than was previously reported ...